EUVIMEDEUVIMED entdecken
Multizentrische Studie

ANTIFON-CLIC®, a new clinical decision support system for the treatment of invasive aspergillosis: is it clinically relevant?

A-L Bienvenu, V Leray, C Guichon, S Bourget, C Chapuis, A Duréault, P Pavese, S Roux, E Kahale, W Chaabane, F Subtil, D Maucort-Boulch und 4 weitere

Annales Pharmaceutiques Françaises · 2024

DOI: 10.1016/j.pharma.2023.11.002 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Annales Pharmaceutiques Françaises, 2024. Verfasst von A-L Bienvenu und 15 weiteren Autor:innen. Beteiligte Einrichtung: Service pharmacie, groupement hospitalier nord, hospices civils de Lyon, Lyon, France; Univ Lyon, Malaria Research Unit, SMITh, ICBMS UMR 5246, Lyon,…. Hauptthemen laut MEDLINE: Decision Support Systems, Clinical, Aspergillosis, Nitriles, Pyridines. Die Arbeit nennt 30 Literaturangaben. Gefördert von: Hospices Civils de Lyon.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Invasive aspergillosis (IA) is increasing especially in new groups of patients. Despite advances in management, morbidity and mortality related to IA remain high. Thus, Clinical Decision Support System (CDSS) dedicated to IA are needed to promote the optimal antifungal for each group of patients. PATIENTS AND METHODS: This was a retrospective multicenter cohort study involving intensive care units and medical units. Adult patients who received caspofungin, isavuconazole, itraconazole, liposomal amphotericin B, posaconazole, or voriconazole, for the treatment of IA were eligible for enrollment. The primary objective was the concordance between the clinician's prescription and the prescription recommended by the CDSS. The secondary objective was the concordance according to different hospitals, departments, and indications. RESULTS: Eighty-eight patients (n=88) from three medical hospitals were included. The overall concordance was 97% (85/88) including 100% (41/41) for center A, 92% (23/25) for center B, and 95% (21/22) for center C. There was no significant difference in concordance among the hospitals (P=0.973), the departments (P=1.000), and the indications (P=0.799). The concordance was 70% (7/10) for isavuconazole due to its use as an empirical treatment and 100% (78/78) for the other antifungals. DISCUSSION: The concordance rate was high whatever the hospital, the department, and the indication. The only discrepancy was attributed to the use of isavuconazole as an empirical treatment which is a therapeutic option not included in the CDSS. CONCLUSIONS: This new CDSS dedicated to IA is meeting the clinical practice. Its implementation in routine will help to support antifungal stewardship.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Decision Support Systems, ClinicalAspergillosisNitrilesPyridinesTriazolesAdultHumansAntifungal AgentsCohort Studies

Stichwörter der Autor:innen

Aspergillose invasiveClinical Decision Support SystemClinical evaluationClinical practiceInvasive aspergillosisMulticentric studyOutil d’aide à la décisionPratique cliniqueÉtude multicentriqueÉvaluation clinique

Substanzen

Antifungal AgentsisavuconazoleNitrilesPyridinesTriazoles

Autor:innen und Institutionen

  • Service pharmacie, groupement hospitalier nord, hospices civils de Lyon, Lyon, France; Univ Lyon, Malaria Research Unit, SMITh, ICBMS UMR 5246, Lyon, France. Electronic address: anne-lise.bienvenu@chu-lyon.fr.
  • Service d'anesthésie-réanimation, groupement hospitalier centre, hospices civils de Lyon, Lyon, France.
  • Service d'anesthésie-réanimation, groupement hospitalier nord, Hospices civils de Lyon, Lyon, France.
  • Service pharmacie, CH de Valence, Valence, France.
  • Service de pharmacie, CHU de Grenoble, Grenoble-Alpes, France.
  • Service des maladies infectieuses, centre hospitalier de Valence, Valence, France.

Förderung

  • Hospices Civils de Lyon

Zitieren

APA

Bienvenu, A. L., Leray, V., Guichon, C., Bourget, S., Chapuis, C., Duréault, A., Pavese, P., Roux, S., Kahale, E., Chaabane, W., Subtil, F., Maucort-Boulch, D., Talbot, F., Dode, X., Ghesquières, H., & Leboucher, G. (2024). ANTIFON-CLIC®, a new clinical decision support system for the treatment of invasive aspergillosis: is it clinically relevant?. Annales Pharmaceutiques Françaises. https://doi.org/10.1016/j.pharma.2023.11.002

Vancouver

Bienvenu AL, Leray V, Guichon C, Bourget S, Chapuis C, Duréault A, et al. ANTIFON-CLIC®, a new clinical decision support system for the treatment of invasive aspergillosis: is it clinically relevant?. Annales Pharmaceutiques Françaises. 2024. doi:10.1016/j.pharma.2023.11.002

BibTeX
@article{Bienvenu2024,
  author = {Bienvenu, A-L and Leray, V and Guichon, C and Bourget, S and Chapuis, C and Duréault, A and Pavese, P and Roux, S and Kahale, E and Chaabane, W and Subtil, F and Maucort-Boulch, D and Talbot, F and Dode, X and Ghesquières, H and Leboucher, G},
  title = {ANTIFON-CLIC®, a new clinical decision support system for the treatment of invasive aspergillosis: is it clinically relevant?},
  journal = {Annales Pharmaceutiques Françaises},
  year = {2024},
  doi = {10.1016/j.pharma.2023.11.002}
}
Kostenlos starten →